Clarson Cheril L, Mahmud Farid H, Baker Janet E, Clark Helen E, McKay Wendy M, Schauteet Vicki D, Hill David J
Children's Hospital, London Health Sciences Centre, London, ON, N6A 5W9, Canada.
Endocrine. 2009 Aug;36(1):141-6. doi: 10.1007/s12020-009-9196-9. Epub 2009 Apr 23.
This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance. Obese adolescents (25) aged 10-16 years with a body mass index (BMI) > 95th percentile and insulin resistance (Homeostasis Model Assessment-HOMA) > 3.0 were assessed in a community clinic. A structured lifestyle intervention comprising nutritional and exercise education and motivational support in both individual and group sessions was delivered over 6 months. Subjects were randomized to lifestyle intervention alone or with metformin (1500 g daily). The primary outcome measures were a change in BMI and modification of metabolic risk factors, including insulin resistance, plasma lipids and adipocytokines. Eleven adolescents receiving lifestyle and metformin intervention and 14 receiving lifestyle alone completed the study. BMI decreased by 1.8 kg/m(2) with lifestyle and metformin but did not change with lifestyle alone. HOMA was significantly decreased in the lifestyle intervention group, but not following metformin, while the adiponectin/leptin ratio improved significantly in both groups. Dyslipidemic profiles improved most significantly with metformin. We conclude that metformin in combination with a 6-month structured lifestyle intervention is effective in reducing BMI in obese adolescents but did not improve insulin resistance. Lifestyle intervention, with or without metformin, improved metabolic risk factors such as plasma lipids and adipocytokines.
本研究评估了在结构化生活方式干预基础上加用二甲双胍对降低胰岛素抵抗肥胖青少年体重指数(BMI)的疗效。在社区诊所对年龄为10 - 16岁、体重指数(BMI)>第95百分位数且胰岛素抵抗(稳态模型评估-HOMA)> 3.0的25名肥胖青少年进行了评估。在6个月内实施了包括营养和运动教育以及个体和小组课程中的激励支持在内的结构化生活方式干预。受试者被随机分为仅接受生活方式干预组或加用二甲双胍组(每日1500毫克)。主要结局指标为BMI的变化以及代谢危险因素的改善,包括胰岛素抵抗、血脂和脂肪细胞因子。11名接受生活方式和二甲双胍干预的青少年以及14名仅接受生活方式干预的青少年完成了研究。生活方式加二甲双胍干预组的BMI下降了1.8 kg/m²,而仅生活方式干预组的BMI未变化。生活方式干预组的HOMA显著降低,但二甲双胍组未降低,而两组的脂联素/瘦素比值均显著改善。二甲双胍对血脂异常情况的改善最为显著。我们得出结论,二甲双胍联合6个月的结构化生活方式干预可有效降低肥胖青少年的BMI,但并未改善胰岛素抵抗。无论是否加用二甲双胍,生活方式干预均改善了血脂和脂肪细胞因子等代谢危险因素。